You just read:

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

News provided by

WuXi Biologics

Dec 10, 2018, 20:47 ET